Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2014, Pages

  Li, Edmond C K ^a   Heran, Balraj S ^b   Wright, James M ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; QUINAPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COUGHING; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; HEADACHE; HEART ATRIUM FLUTTER; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; LARYNX EDEMA; MACROALBUMINURIA; MORTALITY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URTICARIA; CEREBROVASCULAR ACCIDENT; HEART DISEASE; META ANALYSIS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; HEART DISEASES; HUMANS; HYPERTENSION; HYPOTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84907235876     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009096.pub2     Document Type: Review

References (40)

1. Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clinical & Experimental Hypertension 1997;19(8):1263-85.
2. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. New England Journal of Medicine 2004;351(19):1952-61.
3. Fogari R, Derosa G, Ferrari I, Corradi L, Zoppi A, Lazzari P, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. American Journal of Hypertension 2008;21(9):1034-9.
4. Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P, et al. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics 2011;17(1):34-43. [DOI: 10.1177/1074248410395018]
5. Fogari R, Zoppi A, Mugellini A, Maffioli P, Preti P, Derosa G. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opinion on Pharmacotherapy 2012;13(8):1091-9.
6. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney International 2000;58(2):762-9.
7. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal 2004;148(1):52-61.
8. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schurnacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008; Vol. 358, issue 15:1547-59.
9. Sozen AB, Kayacan MS, Tansel T, Celebi A, Kudat H, Akkaya V, et al. Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients. Journal of International Medical Research 2009;37(4):996-1002.
10. Spoelstra-de Man AME, van Ittersum FJ, Schram MT, Kamp O, van Dijk RAJM, Ijzerman RG, et al. Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension. Journal of Human Hypertension 2006;20(8):599-611.
11. Akinboboye OO, Chou R-L, Bergmann SR. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. Journal of the American College of Cardiology 2002;40(4):703-9.
12. Spinar J, Vitovec J, Soucek M, Dusek L, Pavlik T, Invesigators C. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Vnitrni Lekarstvi 2009;55(5):481-8.
13. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, Fogari E, et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertension Research - Clinical & Experimental 2011;34(1):145-51.
14. Didangelos TP, Arsos GA, Karamitsos DT, Athyros VG, Georga SD, Karatzas ND. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. Journal of Diabetes & its Complications 2006;20(1):1-7.
15. el-Agroudy AE, Hassan NA, Foda MA, Ismail AM, el-Sawy EA, Mousa O, et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. American Journal of Nephrology 2003;23(5):300-6.
16. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355(9215):1582-7.
17. Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. Journal of Human Hypertension 1997;11 Suppl 2:S61-2.
18. Guntekin U, Gunes Y, Tuncer M, Simsek H, Gunes A. Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients. Advances in Therapy 2008;25(8):775-86.
19. Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. Journal of the American Society of Nephrology 2007;18(6):1889-98.
20. Ichihara A, Hayashi M, Kaneshiro Y, Takemitsu T, Homma K, Kanno Y, et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. American Journal of Kidney Diseases 2005;45(5):866-74.
21. Nakamura T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. European Journal of Clinical Investigation 2010;40(9):790-6.
22. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361(9352):117-24.
23. Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. American Journal of Therapeutics 1999;6(3):161-6.
24. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360(9335):752-60.
25. Rizzoni D, Porteri E, De Ciuceis C, Sleiman I, Rodella L, Rezzani R, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with non insulin-dependent diabetes mellitus. Hypertension 2005;45(4):659-65.
26. Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RAJM, Schalkwijk CG, Ijzerman RG, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. Journal of Human Hypertension 2005;19(6):429-37.
27. Sengul AM, Altuntas Y, Kurklu A, Aydin L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Research & Clinical Practice 2006;71(2):210-9.
28. Shoda J, Kanno Y, Suzuki H. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Internal Medicine 2006;45(4):193-8.
29. Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Therapeutic Apheresis and Dialysis 2004, issue 4:320-7.
30. Tutuncu NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetologica 2001;38(4):157-61.
31. Ulusoy S, Ozkan G, Orem C, Kaynar K, Kosucu P, Kiris A. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Renal Failure 2010;32(8):913-7.
32. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine 2003;349(20):1893-906.
33. Veronesi M, Cicero AFG, Prandin MG, Dormi A, Cosentino E, Strocchi E, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vascular Health & Risk Management 2007;3(6):999-1005.
34. Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008;94(5):573-80.
35. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Available from www.cochrane-handbook.org.
36. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD003823.pub2]
37. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD003822.pub2]
38. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
39. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD000028.pub2]
40. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2]